Previous Article | Next Article ![]()
Journal of Virology, April 2009, p. 3069-3077, Vol. 83, No. 7
0022-538X/09/$08.00+0 doi:10.1128/JVI.01875-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.
and TBK-1
Washington B. Cárdenas,
,
and
Christopher F. Basler*
Department of Microbiology, Mount Sinai School of Medicine, New York, New York 10029
Received 5 September 2008/ Accepted 7 January 2009
The Ebola virus (EBOV) VP35 protein antagonizes the early antiviral alpha/beta interferon (IFN-
/β) response. We previously demonstrated that VP35 inhibits the virus-induced activation of the IFN-β promoter by blocking the phosphorylation of IFN-regulatory factor 3 (IRF-3), a transcription factor that is crucial for the induction of IFN-
/β expression. Furthermore, VP35 blocks IFN-β promoter activation induced by any of several components of the retinoic acid-inducible gene I (RIG-I)/melanoma differentiation-associated gene 5 (MDA-5)-activated signaling pathways including RIG-I, IFN-β promoter stimulator 1 (IPS-1), TANK-binding kinase 1 (TBK-1), and I
B kinase epsilon (IKK
). These results suggested that VP35 may target the IRF kinases TBK-1 and IKK
. Coimmunoprecipitation experiments now demonstrate physical interactions of VP35 with IKK
and TBK-1, and the use of an IKK
deletion construct further demonstrates that the amino-terminal kinase domain of IKK
is sufficient for interactions with either IRF-3 or VP35. In vitro, either IKK
or TBK-1 phosphorylates not only IRF-3 but also VP35. Moreover, VP35 overexpression impairs IKK
-IRF-3, IKK
-IRF-7, and IKK
-IPS-1 interactions. Finally, lysates from cells overexpressing IKK
contain kinase activity that can phosphorylate IRF-3 in vitro. When VP35 is expressed in the IKK
-expressing cells, this kinase activity is suppressed. These data suggest that VP35 exerts its IFN-antagonist function, at least in part, by blocking necessary interactions between the kinases IKK
and TBK-1 and their normal interaction partners, including their substrates, IRF-3 and IRF-7.
Published ahead of print on 19 January 2009.
K.C.P. and W.B.C. contributed equally.
Present address: Laboratorio de Biomedicina, FIMCM, ESPOL, P.O. Box 09-01-5863, Guayaquil, Ecuador.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»